Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis

抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效

基本信息

  • 批准号:
    8497027
  • 负责人:
  • 金额:
    $ 35.37万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-01-15 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Despite recent increase in the number of antifungal agents available for the treatment of systemic fungal diseases, morbidity and mortality are substantial; noting that invasive candidiasis (IC) is the fourth most common cause of nosocomial bloodstream infection in the United States chiefly among immunocompromised patients and that IC is associated with the highest crude mortality of all bloodstream infections (ca. 40%). Given the dismal outcomes for IC, combination of antifungal agents is increasingly being considered. However, pharmacodynamic (PD) properties for established and novel combinations of antifungal agents are ill-defined in terms of dose selection, dose fractionation, predictive PD index (PDI), and post-antibiotic effect (PAE) in relation to treatment efficacy and host toxicity. The major goal of this research project is to characterize the PD properties of established and novel combinations of antifungal agents in a neutropenic murine model of IC, aiming for novel insights and progress in IC beyond the present scope of research and therapy, which is usually single agent-based. Towards enabling in vivo PD studies, we made exciting progress in combination delivery (co-delivery) of amphotericin B (AmB) with other antifungal agents via self-assembled polymers, fulfilling requirements in solubility, safety, stability, and synergy, which ca now be achieved by the coincident action of combination antifungal agents administered simultaneously. We hypothesize that AmB and 5-fluoro- cytosine (5-FC) delivered together intravenously will exert potent antifungal activity, with low or no conversion of 5-FC into 5-fluorouracil (5-FU), observed after oral 5-FC, resulting in decreased bone marrow toxicity. We hypothesize that AmB and 17-allylamino-17-demethoxygeldanamycin (17-AAG), a heat shock protein 90 (Hsp90) inhibitor, will exert potent antifungal activity with low renal toxicity. Specifc Aims: (1) To characterize PK of micellar AmB and 5-FC, antifungal activity in a neutropenic murine model of IC, and toxicity in single and multiple dose (dose fractionation) regimens: PAE; predictive PDI (for maximum antifungal efficacy and optimal dosing regimen); and hematology relative to oral 5-FC. (2) To characterize PK of micellar AmB and 17-AAG, antifungal activity in a neutropenic murine model of IC, and toxicity in single and multiple dose regimens: PAE; predictive PDI; and renal and hepatic toxicity. (3) To characterize PK of micellar AmB, 5-FC, and micellar 17- AAG, antifungal activity in a neutropenic murine model of IC, and toxicity in single and multiple dose regimens: PAE; predictive PDI; hematology; renal toxicity; and histopathology in major organs.
描述(由申请人提供):尽管最近可用于治疗全身性真菌疾病的抗真菌剂的数量增加,但发病率和死亡率是相当大的;注意到侵袭性念珠菌病(IC)是美国主要在免疫功能低下患者中的医院内血流感染的第四大常见原因,并且IC与所有血流感染的最高粗死亡率相关(约20%)。40%)。鉴于IC的不良结局,越来越多地考虑联合使用抗真菌药物。然而,在剂量选择、剂量分割、预测性PD指数(PDI)和抗生素后效应(PAE)方面,已建立和新型抗真菌药物组合的药效学(PD)特性定义不清,与治疗疗效和宿主毒性有关。本研究项目的主要目标是在IC的血小板减少小鼠模型中表征已建立和新型抗真菌药物组合的PD特性,旨在超越目前的研究和治疗范围(通常基于单药),获得IC的新见解和进展。为了实现体内PD研究,我们在通过自组装聚合物组合递送(共递送)阿替霉素B(Am B)与其他抗真菌剂方面取得了令人兴奋的进展,满足了溶解性、安全性、稳定性和协同作用的要求,这可以通过同时施用的组合抗真菌剂的同时作用来实现。我们假设,AmB和5-氟胞嘧啶(5-FC)一起静脉给药将发挥有效的抗真菌活性,口服5-FC后观察到5-FC转化为5-氟尿嘧啶(5-FU)的转化率较低或无转化,导致骨髓毒性降低。我们推测AmB和17-烯丙基氨基-17-去甲氧基格尔德霉素(17-AAG),热休克蛋白90(Hsp 90)抑制剂,将发挥有效的抗真菌活性与低肾毒性。具体目标:(1)表征胶束AmB和5-FC的PK、IC的血小板减少小鼠模型中的抗真菌活性以及单次和多次给药(剂量分级)方案中的毒性:PAE;预测性PDI(最大抗真菌疗效和最佳给药方案);以及相对于口服5-FC的血液学。(2)表征胶束AmB和17-AAG的PK、IC的血小板减少小鼠模型中的抗真菌活性以及单次和多次给药方案中的毒性:PAE;预测性PDI;以及肾脏和肝脏毒性。(3)表征胶束AmB、5-FC和胶束17- AAG的PK、IC的血小板减少小鼠模型中的抗真菌活性以及单次和多次给药方案中的毒性:PAE、预测性PDI、血液学、肾毒性和主要器官的组织病理学。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(3)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Glen S. Kwon其他文献

Polymeric micelle nanocarriers in cancer research
Polymeric Micelles for Multi-Drug Delivery in Cancer
  • DOI:
    10.1208/s12249-014-0251-3
  • 发表时间:
    2014-12-11
  • 期刊:
  • 影响因子:
    4.000
  • 作者:
    Hyunah Cho;Tsz Chung Lai;Keishiro Tomoda;Glen S. Kwon
  • 通讯作者:
    Glen S. Kwon
Soluble Self-Assembled Block Copolymers for Drug Delivery
  • DOI:
    10.1023/a:1011991617857
  • 发表时间:
    1999-01-01
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    Glen S. Kwon;Teruo Okano
  • 通讯作者:
    Teruo Okano
Production of paclitaxel-loaded PEG-emb/em-PLA micelles using PEG for drug loading and freeze-drying
使用聚乙二醇进行药物负载和冷冻干燥来生产紫杉醇负载的聚乙二醇-乳化/包埋-聚乳酸微球
  • DOI:
    10.1016/j.jconrel.2022.08.032
  • 发表时间:
    2022-10-01
  • 期刊:
  • 影响因子:
    11.500
  • 作者:
    Morteza Rasoulianboroujeni;Lauren Repp;Hye Jin Lee;Glen S. Kwon
  • 通讯作者:
    Glen S. Kwon
Paclitaxel Prodrugs with Sustained Release and High Solubility in Poly(ethylene glycol)-b-poly(ε-caprolactone) Micelle Nanocarriers: Pharmacokinetic Disposition, Tolerability, and Cytotoxicity
  • DOI:
    10.1007/s11095-007-9451-9
  • 发表时间:
    2007-10-03
  • 期刊:
  • 影响因子:
    4.300
  • 作者:
    M. Laird Forrest;Jaime A. Yáñez;Connie M. Remsberg;Yusuke Ohgami;Glen S. Kwon;Neal M. Davies
  • 通讯作者:
    Neal M. Davies

Glen S. Kwon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Glen S. Kwon', 18)}}的其他基金

Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly
使用纤连蛋白组装的有效抑制剂对肿瘤微环境进行直接治疗干预
  • 批准号:
    10409814
  • 财政年份:
    2021
  • 资助金额:
    $ 35.37万
  • 项目类别:
Direct therapeutic intervention of the tumor microenvironment with a potent inhibitor of fibronectin assembly
使用纤连蛋白组装的有效抑制剂对肿瘤微环境进行直接治疗干预
  • 批准号:
    10199263
  • 财政年份:
    2021
  • 资助金额:
    $ 35.37万
  • 项目类别:
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
用于联合治疗的寡(乳酸)n-前药纳米药物
  • 批准号:
    10371257
  • 财政年份:
    2021
  • 资助金额:
    $ 35.37万
  • 项目类别:
Oligo(lactic acid)n-Prodrug Nanomedicines for Combination Therapy
用于联合治疗的寡聚(乳酸)n-前药纳米药物
  • 批准号:
    10597075
  • 财政年份:
    2021
  • 资助金额:
    $ 35.37万
  • 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
  • 批准号:
    8605161
  • 财政年份:
    2013
  • 资助金额:
    $ 35.37万
  • 项目类别:
Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
抗真菌药物的联合给药:侵袭性念珠菌病的毒性和功效
  • 批准号:
    8786047
  • 财政年份:
    2013
  • 资助金额:
    $ 35.37万
  • 项目类别:
Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology
用于“See”的三峰聚合物胶束
  • 批准号:
    8298518
  • 财政年份:
    2011
  • 资助金额:
    $ 35.37万
  • 项目类别:
Tri-modal Polymeric Micelles for 'See & Treat' Applications in Surgical Oncology
用于“See”的三峰聚合物胶束
  • 批准号:
    8175145
  • 财政年份:
    2011
  • 资助金额:
    $ 35.37万
  • 项目类别:
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY
用于药物输送的生物特异性聚合物酶缀合物
  • 批准号:
    6262537
  • 财政年份:
    2001
  • 资助金额:
    $ 35.37万
  • 项目类别:
BIOSPECIFIC POLYMER ENZYME CONJUGATES FOR DRUG DELIVERY
用于药物输送的生物特异性聚合物酶缀合物
  • 批准号:
    6489389
  • 财政年份:
    2001
  • 资助金额:
    $ 35.37万
  • 项目类别:

相似海外基金

有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
  • 批准号:
    24K17671
  • 财政年份:
    2024
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
  • 批准号:
    MR/X014010/1
  • 财政年份:
    2023
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Research Grant
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
  • 批准号:
    559052-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
  • 批准号:
    22K05333
  • 财政年份:
    2022
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
  • 批准号:
    559052-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 35.37万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
  • 批准号:
    10024667
  • 财政年份:
    2020
  • 资助金额:
    $ 35.37万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    9909193
  • 财政年份:
    2020
  • 资助金额:
    $ 35.37万
  • 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
  • 批准号:
    10248529
  • 财政年份:
    2020
  • 资助金额:
    $ 35.37万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    10484014
  • 财政年份:
    2020
  • 资助金额:
    $ 35.37万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    10654834
  • 财政年份:
    2020
  • 资助金额:
    $ 35.37万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了